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Background Studies on the association between heavy coffee consumption and risk of less 
frequently diagnosed cancers are scarce. We aimed to quantify the association between 
filtered, boiled, and total coffee consumption and the risk of bladder, esophageal, kidney, 
pancreatic, and stomach cancers. 
Methods We used data from the Norwegian Women and Cancer Study and the Northern 
Sweden Health and Disease Study. Information on coffee consumption was available for    
193 439 participants. We used multivariable Cox proportional hazards models to calculate 
hazard ratios (HR) with 95% confidence intervals (CI) for the investigated cancer sites by 
category of total, filtered, and boiled coffee consumption. 
Results Heavy filtered coffee consumers (≥4 cups/day) had a multivariable adjusted HR of 
0.74 of being diagnosed with pancreatic cancer (95% CI 0.57-0.95) when compared with light 
filtered coffee consumers (≤1 cup/day). We did not observe significant associations between 
total or boiled coffee consumption and any of the investigated cancer sites, neither in the 
entire study sample nor in analyses stratified by sex. We found an increased risk of bladder 
cancer among never smokers who were heavy filtered or total coffee consumers, and an 
increased risk of stomach cancer in never smokers who were heavy boiled coffee consumers. 
Conclusion Our data suggest that increased filtered coffee consumption might reduce the risk 
of pancreatic cancer. We did not find evidence of an association between coffee consumption 
and the risk of esophageal or kidney cancer. The increased risk of bladder and stomach cancer 







Many studies have aimed to clarify the mechanism(s) behind the biological effects of coffee 
components. Caffeine, the coffee diterpens kahweol and cafestol, and chlorogenic acid have 
been identified as the compounds that contribute most to the anticarcinogenic properties of 
roasted coffee (1-8). Of these compounds, the diterpenes deserve specific attention, since 
coffee brewing technique affects diterpene content to a large extent. Indeed, the diterpene 
content of boiled, unfiltered coffee may be as much as 60 times higher than that of filtered 
coffee (9). 
In the past 2 decades, numerous studies have been conducted with the aim to quantify the 
association between coffee consumption and the risk of the most frequently diagnosed 
cancers. However, similar research that used rare cancer sites as the main outcome is less 
common. In a recently published meta-analysis by Wu et al, male coffee consumers and non-
smoking coffee consumers were found to have an increased risk of bladder cancer (10), 
whereas the International Agency for Research on Cancer concluded there was no consistent 
evidence of an association between drinking coffee and bladder cancer risk (11). On the other 
hand, the meta-analyses did not reveal any association between coffee consumption and the 
risk of esophageal, pancreatic, or stomach cancer (12-14). Similarly, the authors of the World 
Cancer Research Fund's second expert report found limited evidence of an association 
between coffee consumption and the risk of renal and pancreatic cancer (15, 16). 
Norway and Sweden rank second and fourth in the world, respectively, in average per 
capita coffee consumption (17). We pooled the data from two Nordic cohorts: the Norwegian 
Women and Cancer (NOWAC) Study and the Northern Sweden Health and Disease Study 
(NSHDS), in order to explore the association between filtered, boiled, and total coffee 
consumption and the risk of bladder (worldwide age-standardized rate (ASR) per 100 000 – 
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5.3), esophageal (worldwide ASR – 5.9), kidney (worldwide ASR – 4.4), pancreatic (ASR – 
4.2) and stomach (worldwide ASR – 12.1) cancer (18). 
Methods 
Participants 
We included participants from the NOWAC Study and the NSHDS. The data from these 
studies were merged into one dataset, which was used in the present paper. Detailed 
information on these two cohorts are available elsewhere (19, 20). In short, the NOWAC 
study was started in 1991 and consists of random samples of 172 000 Norwegian women aged 
30-70 years that completed a questionnaire regarding their lifestyle, diet, and health status 
(overall response rate: 52.7%). Follow-up information was also collected on two occasions, 
with approximately 6-8 years between data collection(s). The NSHDS was started in 1985; it 
consists of a biobank and related survey data from about 166 000 men and women in 
northernmost Sweden, including three population-based sub-cohorts: the Västerbotten 
Intervention Programme (VIP) cohort (participants aged 30, 40, 50 or 60 years), the 
MONICA cohort (participants aged 25-74 years), and the mammography screening cohort 
(women aged 50-69 years). Dietary data are available in the VIP and MONICA cohorts and 
are administered by the Northern Sweden Diet Database (NSDD). By December 31, 2014 
Food frequency questionnaire (FFQ) data from 103 256 unique individuals in the NSDDS 
were available for this study after exclusion of participants with incomplete food-intake data, 
extreme food intakes, extreme energy intakes, and implausible height and weight. Details of 
this selection procedure are described elsewhere (21).  
All participants gave written informed consent. The NOWAC Study was approved by the 
Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate, 
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whereas the coffee study within the NSHDS was approved by the Regional Ethical Review 
Board of Northern Sweden (registration number: 2013/332/31).  
The NOWAC Study contributed 101 320 women to the present analysis, whereas the 
NSHDS cohort initially contributed 103 256 participants. As the questionnaires sent out 
during the first wave of data collection in the NOWAC Study (1991–1992) did not include 
questions on diet, we chose not to use the information collected at that time. We further 
excluded those with prevalent cancer other than non-melanoma skin cancer at baseline, those 
who emigrated or died before the start of follow-up (N=8101), those that had missing 
information on coffee consumption (N=1615), and those with total energy intake above 15 
000 kJ or below 2500 kJ/day (N=1362). Our final sample consisted of 193 439 participants 
(94 286 from the NOWAC Study and 99 153 from NSDD), of whom 145 247 (75.1 %) were 
women and 48 192 (24.9%) were men. 
 
Assessment of coffee consumption and covariates  
In the NOWAC FFQ, women answered the following question on coffee consumption: “How 
many cups of each kind of coffee (boiled, filtered, instant) did you usually drink during the 
past year?’’ For each brewing method, women could choose from the following answers: 
never/seldom, 1–6 cups/week, 1 cup/day, 2–3 cups/day, 4–5 cups/day, 6–7 cups/day, and ≥8 
cups/day. In the NSHDS cohort, coffee consumption was measured as the number of 
occasions on which a participant consumed filtered or boiled coffee with the following 
alternatives: never, a few times/year, 1-3 times/month, 1 time/week, 2-3 times/week, 4-6 
times/week, 1 time/day, 2-3 times/day, and >4 times/day. For the purpose of this paper, we 
assumed that 1 time/day from the NSHDS cohort matched 1 cup/day from the NOWAC 
cohort. We calculated total coffee consumption by summing the frequencies of filtered, 
boiled, and instant coffee in the NOWAC cohort and filtered and boiled coffee in the NSHDS 
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cohort. Finally, filtered, boiled, and total coffee consumption was categorized as light 
consumption (≤1 cup/day), moderate consumption (>1-< 4 cups/day), and heavy consumption 
(≥4 cups/day). 
Information on smoking status (never, former, or current), alcohol consumption, body 
mass index (BMI), total energy intake, and self-reported history of diabetes were also 
available from both cohorts. 
 
Follow-up and end points 
In the NOWAC cohort, the unique 11-digit personal number assigned to every legal resident 
in Norway was used to obtain information on cancer incidence through linkage to the 
Norwegian Cancer Registry, and to obtain information on death and emigration through 
linkage to the Norwegian Central Population Register. In the NSDDS cohort, the unique 12-
digit personal number was used to obtain information on cancer end-points through linkage to 
the regional branch of the Swedish Cancer Registry; mortality end-points were identified 
through linkage to the Swedish National Cause-of-death Registry. 
 The 7th Revision of the International Statistical Classification of Diseases, Injuries and 
Causes of Death was used to classify bladder (181.0-181.9), esophageal (150.0-150.9), kidney 
(180.0-180.9), pancreatic (157.0-157.9), and stomach (151.0-151.9) cancer cases in the 
national and regional cancer registries. 
 
Statistical analysis 
We calculated person-years from start of follow-up until diagnosis of any incident invasive 
cancer other than non-melanoma skin cancer, death, emigration, or the end of the study period 
(31 December 2014), whichever occurred first. 
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We used Cox proportional hazards regression models to calculate hazard ratios (HRs) 
with 95% confidence intervals (CIs) for the association between coffee consumption and the 
risk of developing bladder, esophageal, kidney, pancreatic, or stomach cancer for the entire 
cohort and in men and women separately. Light coffee consumers (≤1 cup/day) were used as 
the reference group, as the number of cases among “never/seldom” coffee consumers was 
low. We also believed that “never/seldom” coffee consumers could differ from the study 
population who reported consuming coffee more frequently, making them less appropriate as 
a reference group, as seldom consuming or abstaining from coffee is relatively uncommon in 
Scandinavia.  
We used attained age as the underlying time scale. All models were stratified by study 
cohort. The final models for each cancer site were adjusted for a variety of the following a 
priori selected covariates: sex, smoking status (never, former, current), body mass index 
(BMI, ≤18.49, 18.5-24.9, 25-29.9, and ≥30 kg/m2), alcohol consumption (0, 0.1-3.99, 4-9.99, 
≥10 g/day), and self-reported history of diabetes (yes/no). In addition, the analyses of filtered 
coffee were adjusted for boiled coffee consumption and vice-versa. 
The proportional hazards assumption was assessed by Schoenfeld residuals. To test for 
linear trend, a median value was assigned to each category of the ordinal coffee consumption 
variable, which was then modeled as a continuous variable in the analysis. 
To assess a possible non-linear relationship between coffee consumption and the study 
outcomes, we modeled restricted cubic splines with four knots, with its locations based on 
Harrell’s recommended percentiles of the total and filtered coffee consumption (22). The 
restricted cubic splines for boiled coffee were modeled with three knots, positioned at the 25th, 
60th, and 95th percentiles of the coffee distribution. We used a Wald-type test to assess if the 
coefficients of the second and third spline in filtered and total coffee analyses, and second 




We assessed possible interactions between coffee consumption and BMI, as the 
antioxidant effects of coffee might be modified by this factor (23). We also decided to 
conduct analyses of all the outcomes stratified by smoking status (never/ever), as the renal 
clearance of caffeine was found to be different between smokers and non-smokers (24, 25), 
and a possible association between coffee consumption and the risk of bladder cancer among 
never smokers has been previously reported (10, 26). 
To check for possible reverse causality, we performed analyses in which we excluded 
participants who were diagnosed with one of the cancers under investigation during the first 
year of follow-up. As part of sensitivity analyses, we assessed the effect of coffee 
consumption on the risk of the five cancer sites by applying Fine and Grey competing risk 
regression models, with all other incident cancers as competing risk (27). Finally, we 
conducted analyses of all of the outcomes with additional adjustment for total energy intake 
(kJ/day), and the analyses of pancreatic cancer in which we also adjusted for red meat intake 
(occasions/day). 




During an average of 13.6 years of follow-up and more than 2.6 million person-years, a total 
of 19 733 cancer cases were identified, among them 479 (2.4%) bladder cancers, 97 (0.5%) 
esophageal cancers, 475 (2.5%) kidney cancers, 491 (2.5%) pancreatic cancers, and 281 
(1.4%) stomach cancers.  
The distribution of cancer cases was similar across coffee consumption categories. Most 
men and women reported moderate coffee consumption. Light coffee consumers were the 
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youngest at baseline, and were more likely to have been never smokers, as opposed to heavy 
coffee consumers, who were both the oldest and more often current smokers. (Table 1).  
Filtered coffee was drunk most frequently. Most of the men reported being moderate filtered 
coffee consumers (43.1%), while 38.5% of the women were light and 34.2% were moderate 
filtered coffee consumers. Boiled coffee consumption was uncommon in both men and 
women, with 81.4% and 85.1%, respectively, reporting light boiled coffee consumption. 
(Supplementary table 1). Moreover, 97.4% of the heavy filtered coffee consumers were light 
boiled coffee consumers. On the other hand 78.9% of the heavy boiled coffee consumers 
reported drinking no more than 1 cup of filtered coffee per day. Overall, only 768 participants 
in the cohort reported drinking at least 4 cups of both filtered and boiled coffee per day 
(Supplementary table 2).  
We did not find any evidence of an association between total coffee consumption and risk 
of bladder, esophageal, kidney, pancreatic, or stomach cancer in moderate, or heavy total 
coffee consumers compared to light total coffee consumers (Table 2). This was also true in 
sex-specific analyses (Table 3). Compared to light total coffee consumers, heavy total coffee 
consumers had a multivariable-adjusted HR of 0.83 of being diagnosed with pancreatic cancer 
(95% CI 0.62-1.11). Corresponding HRs for bladder, esophageal, kidney and stomach cancers 
were 1.34 (95% CI 0.94-1.90), 0.83 (95% CI 0.42-1.61), 0.99 (95% CI 0.74-1.33), and 0.88 
(95% CI 0.61-1.28), respectively. In addition, there was no evidence of a dose-response 
relationship in any of the investigated outcomes. We observed an 87% increased risk of 
bladder cancer (95% CI 1.01-3.45; p for trend across categories=0.03) in never smokers who 
were also heavy total coffee consumers compared to never smokers who were light coffee 
consumers.  
We found a significantly reduced risk of pancreatic cancer for both moderate (HR: 0.79, 
95% CI 0.64-0.99) and heavy filtered coffee consumers (HR: 0.74, 95% CI 0.57-0.95; p for 
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trend across categories=0.01) (Table 4). The association remained significant in never 
smokers (moderate vs. light consumers HR: 0.60, 95% CI 0.41-0.87; heavy vs. light 
consumers HR: 0.60, 95% CI 0.35-1.01; p for trend across categories=0.01) (Table 7), and 
borderline significant in women (Table 5). We did not observe a significant association 
between filtered coffee consumption and risk of pancreatic cancer in men (Table 5) or in ever 
smokers (Table 7). Similar to a total coffee consumption, heavy filtered coffee consumption 
was associated with an increased risk of bladder cancer in never smokers (HR: 1.86, 95% CI 
1.12-3.10). An increased filtered coffee consumption was not associated with the risk of 
esophageal, kidney, or stomach cancer in the total cohort, nor was an association found in 
analyses stratified by gender and smoking status. 
We found an increased risk of bladder cancer in women (Table 6) and in never smokers 
(Table 7) who were moderate boiled coffee consumers (HR: 1.58, 95% CI 1.03-2.05; HR: 
1.64, 95% CI 1.03-2.62, respectively), with no significant trend across consumption 
categories (p=0.56 and p=0.06, respectively). Finally, never smokers who were also heavy 
boiled coffee consumers had more than twice the risk of stomach cancer compared to never 
smokers who were light boiled coffee consumers (HR: 2.14, 95% CI 1.10-4.16; p for trend 
across categories=0.04). 
We did not observe any departure from linearity between filtered, boiled, and total intake 
and the study outcomes (data not shown). The associations between 1-cup/day increase in 
each coffee type and the risk of each of the study outcomes, estimated from the restricted 
cubic splines models are presented in Figures 1-3. The figure 2 show a per-cup, statistically 
significant, reduced risk of pancreatic cancer among those who increased their filtered coffee 
consumption from 2 to 6 cups/day. 
The test of Schoenfeld residuals did not indicate a violation of the proportional hazards 
assumption. We found no evidence of effect modification between coffee consumption and 
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BMI for any of the outcomes. The risk estimates for bladder, esophageal, kidney, and 
pancreatic cancers in analyses which did not include cancer cases diagnosed during the first 
year of follow-up were similar to those from the analyses that included the entire study 
sample. On the other hand, the estimates for stomach cancer were stronger in the analyses that 
excluded cases diagnosed during the first year of follow-up were excluded (data not shown). 
The subhazard ratios from the competing risk regression models were similar to the estimates 
from the ordinary Cox proportional hazards regression models (data not shown). Finally, our 
conclusions remained the same after the models were additionally adjusted for total energy 
intake and red meat consumption (data not shown).   
 
Discussion 
The data from this large joint cohort did not provide evidence of an association between total 
coffee consumption and the risk of esophageal, kidney, or stomach cancer. Further, no anti-
carcinogenic effect of diterpene rich boiled unfiltered coffee in comparison with filtered 
coffee was found. On the contrary, in analyses stratified by brewing technique, we found that 
increased filtered coffee consumption was associated with a reduced risk of pancreatic cancer. 
We observed an increased risk of bladder cancer for never smokers who reported consuming 
≥4 cups/day of total coffee, as well as an increased risk of stomach cancer for never smokers 
who were heavy boiled coffee consumers. 
Bladder cancer 
None of the significant associations we observed between coffee consumption and risk of 
bladder cancer are in line with the results of the study by Jacobsen et al, which included       
16 555 Norwegian men and women (28), and the study by Kurahashi et al, conducted among 
more than 100 000 Japanese men and women (26). On the other hand, Wu et al found a meta-
odds ratio (OR) of 1.33 (95% CI 1.19-1.48) after pooling the results from 25 case-control and 
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five cohort studies. Our results for never smokers confirmed the findings of this meta-
analysis, in which the authors reported a meta-OR of 1.72 (95% CI: 1.25 to 2.35) for never 
smokers in the highest coffee consumption category (10). A proposed mechanism that 
explains why the increased risk is observed only in never smokers involves a stimulating 
effect of caffeine on liver enzymes CYP1A2 and NAT2. The activation of some carcinogens 
from cigarette smoking such as polycyclic aromatic hydrocarbons might be increased by the 
said enzymes (10, 26, 29). As the metabolism of caffeine might be faster in smokers due to a 
shared metabolic pathway by nicotine and caffeine (30, 31), the potential carcinogenic effect 
of coffee might more pronounced in never smokers.  
Esophageal cancer 
Jacobsen et al found no association between coffee consumption and the risk of 
esophageal cancer in a study that included only 22 cases (28). In a more recent study from 
Japan, Naganuma et al found an inverse association between coffee consumption and the risk 
of oral cavity, pharyngeal, and esophageal cancers combined. They reported a 49% decreased 
risk for those who drank at least 1 cup/day of coffee compared to abstainers (95% CI 23%-
67%), with an inverse association that was consistent regardless of sex (32). However, in a 
recent systematic review, Islami et al stated that there was little evidence of an association 
between coffee consumption and the risk of esophageal cancer after summarizing the results 
from 22 observational studies (12).    
Pancreatic cancer 
Our results regarding pancreatic cancer and total coffee consumption are in line with 
findings from a meta-analysis that included 15 case-control and 12 cohort studies and adjusted 
for smoking exposure (13). The authors reported a meta-risk ratio of 1.01 (95% CI 0.99-1.04) 
for a 1-cup/day increase. Similarly, no association was found in two studies from Norway, 
one from Finland, or in a study from Sweden that included participants from the VIP cohort of 
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the NDDS (28, 33-35). Guertin et al used data from the NIH-AARP Diet and Health cohort 
and did not observe an association between total, caffeinated, or decaffeinated coffee 
consumption and the risk of pancreatic cancer either men or women (36). The data from the 
VIP cohort further indicated that the consumption of ≥4 cups/day of boiled coffee was 
associated with a 2.5-fold (95% CI 1.15-5.50) increased risk of pancreatic cancer compared to 
consumption of >1 cup/day. The analysis, however, was severely underpowered,  as the 
number of cases in the highest boiled coffee consumption group was only eight (34). One of 
the possible explanations of the difference in the association between filtered and boiled 
coffee and the risk of pancreatic cancer might be the difference in diet between consumers of 
these coffee types. Boiled coffee consumers are more likely to have more traditional food 
habits, and are less adapted to a modern, more sedentary lifestyle compared to filtered coffee 
consumers (37). This may also explain the general lack of anti-carcinogenic effect showed 
among consumers of boiled coffee compared with consumers of filtered coffee in this study.  
Increased coffee consumption has been associated with a lower risk of type 2 diabetes (38), 
which is an established risk factor for pancreatic cancer (39). Chlorogenic acid, one of the 
components of roasted coffee, was found to reduce glucose levels, thus increasing insulin 
sensitivity and reducing the risk of cancer, in addition to its antioxidant capacity (7, 40). An 
anticancerogenic effect of coffee diterpens, kahweol and cafestol seems unlikely based on our 
findings, as concentration of these compounds in filtered coffee is very small (41).    
Renal cancer   
Stensvold et al found no association between coffee consumption and the risk of renal 
cancer in a cohort of 43 000 Norwegian men and women, a case-control study from Italy by 
Montella et al came to the same conclusion (33, 42). Contrary to these studies, Nilsson et al 
found a 70% reduced risk of renal cancer among subjects from the VIP cohort with a total 
coffee consumption of ≥4 cups/day compared to those who drank >1 cup/day. However, only 
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56 cases of renal cancer were available for the VIP analysis, compared to 462 cases from the 
present study. The authors did not observe any preparation-specific association for filtered or 
boiled coffee (34).     
Stomach cancer 
Zeng et al found a relative risk (RR) of stomach cancer of 1.18 (95% CI 0.90-1.15) for the 
highest coffee consumption category after pooling the results from 15 cohort studies, and a 
RR of 1.07 (95% CI 0.95-1.21) for every 3-cup/day increase in total coffee consumption (14). 
No association between coffee consumption and stomach cancer was found in the studies by 
Jacobsen et al, Stensvold et al, or Nilsson et al, nor was an association reported in two more 
recent studies from Finland and Singapore (28, 33-35, 43). 
 
Strengths and limitations 
In addition to its prospective design, our study had sufficient sample size and statistical 
power to detect differences between coffee consumption groups in most of the studied 
outcomes. The high prevalence of coffee consumers in Scandinavia allowed us to explore the 
impact of heavy coffee consumption on the risk of cancer. Linkage to cancer registries via the 
unique personal identification numbers in Norway and Sweden allowed us to obtain almost 
complete follow-up of cancer cases. 
The response rate of 52.7% of the NOWAC Study, and the participation rate of 48-79% in 
the sub-cohorts of the NSDDS are similar to other population-based cohorts. Both the 
NOWAC Study and the NSDDS have been shown to be truly population-based in validation 
studies, with no significant differences in lifestyle factors and incidence rates between 
responders and non-responders (44-47). Thus, the external validity of this study is considered 
to be acceptable. 
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24-h dietary recall studies conducted to validate the FFQs used in the NOWAC Study and 
NSDDS cohorts showed a high validity of data on coffee consumption (Spearman’s 
correlation coefficients r=0.82 and r=0.72 respectively) (48-50). Similarly, the test-retest 
reliability of self-reported history of diabetes, weight, and height in these Norwegian cohorts 
was found to be acceptable (51-53).  
Regarding brewing technique, the NOWAC Study and the NSDDS cohorts are, to the best 
of our knowledge, the only large population-based studies available that distinguish clearly 
between filtered and non-filtered coffee consumption.  
There are several limitations in our study. Analyses of esophageal cancer were somewhat 
statistically underpowered. This also holds true for sex-specific analyses, in addition to a 
relatively small number of stomach cancer cases among men. Similarly, subgroup analyses by 
smoking status may have lacked statistical power in the analyses of bladder, esophageal and 
stomach cancer sites, and this problem was more pronounced in the analyses of never 
smokers.     
We lacked information on caffeination status, as this information was not available from 
the questionnaires. However, as the consumption of decaffeinated coffee is uncommon in 
Norway and Sweden, we believe that the observed estimates reflect the association between 
caffeinated coffee consumption and the study outcomes (54). Similarly, total coffee 
consumption in the present study might have been underestimated, as we did not have 
information on the consumption of coffee drinks such as macchiato, espresso, cappuccino, or 
café latte. In addition, we lacked information on instant coffee consumption from the NSDDS 
cohort. However, from a chemical point of view, instant coffee is prepared by freeze-drying 
filtered coffee, thus this distinction is of less importance from a misclassification of brewing 
technique perspective. Further, consumption of these types of coffee drinks was relatively rare 
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at the time of data collection. Therefore, the underestimation of total coffee consumption is 
likely negligible.  
Even though validation studies have shown a high validity of the data on coffee 
consumption, misclassification is still possible, as coffee consumption was self-reported. In 
addition, the units of measurement of coffee consumption were different between the cohorts 
(occasions/day vs. cups/day), and there may have been individual variation in cup size as 
well. Given this, there is a potential for misclassification in total coffee consumption as a 
consequence of adding up categorical variables; however, even if misclassification is present, 
it is most likely non-differential. 
Finally, residual confounding of some factors cannot be ruled out. For example, we did 
not adjust for tea consumption, as this information was not available from the NOWAC Study 
questionnaire. Additional adjustment for tea consumption could have attenuated the observed 
associations, as tea and coffee share some biologically active compounds.     
In conclusion, based on the data from the NOWAC and NSDDS cohorts, an increased 
consumption of filtered coffee was associated with a lower risk of pancreatic cancer, and this 
effect was more pronounced in never smokers. No association was found between coffee 
consumption and the risk of esophageal or kidney cancer. The significantly increased risk of 
bladder and stomach cancer we observed was confined to never smokers, although the 
analyses were hampered by the small number of cases. 
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